Skip to content
Friday, November 20, 2026
Responsive Menu
Home
Healthcare Newsdesk
The Latest UK Healthcare News brought to you by NTSI
Search
Search
Home
Care Home News
Carers
Medicine & Clinical Practice
Arthritis
Brain Conditions
Cancer
Colds and Flu
Diabetes
Diet & Exercise
Eyecare
Menopause
Mens Health
Mental Wellbeing
Psychology
Rare Medical Conditions
Smoking
Women’s Health
Physiotherapy
Private Practice
Recruitment
Wellbeing at Work
Home
Clinical News
Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves disease
Clinical News
Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves disease
June 12, 2024
Articles From The BMJ
Post navigation
Efficacy and safety of transcutaneous electrical acupoint stimulation for the management of primary dysmenorrhoea: protocol for a randomised controlled trial in China
Assessing the risks for stillbirth in Sao Paulo, Brazil: protocol for a multidisciplinary case-control study – FetRisks